Dabur India posts Q4 FY25 consolidated PAT at Rs. 320.13 Cr
The company has posted net profit of Rs. 1,767.63 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 1,767.63 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 55.36 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs.168.16 crores for the Financial Year ended March 31, 2025
Glatiramer Acetate is the generic version of Copaxone 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
The change of name has been carried on pursuant to the Scheme of Amalgamation
The company's first-ever corporate-level submission to EcoVadis builds on years of operational and environmental excellence
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
Topiramate is indicated as a treatment of epilepsy and migraine
This outcome reflects Innoxel Lifesciences' ongoing commitment to maintaining the highest standards of quality, compliance, and regulatory excellence
Subscribe To Our Newsletter & Stay Updated